Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. - Wikidata - awgldk - TriplyDB

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

http://www.wikidata.org/entity/Q36380424

about

Immune Checkpoint Blockade in Cancer Therapy Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Radiation meets immunotherapy - a perfect match in the era of combination therapy?The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations Novel immune checkpoint blocker approved for the treatment of advanced melanoma Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract.Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.Radiotherapy and immune checkpoint blockades: a snapshot in 2016.Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model.Emerging immunotherapy strategies in breast cancer.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Optimizing tumor immune response through combination of radiation and immunotherapy.Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review.Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives.Irradiation and immunotherapy: From concept to the clinic.Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignancies Merkel Cell Carcinoma Therapeutic Update.Clinical review of treatment outcomes and patterns of failure with adjuvant radiotherapy in node-positive malignant melanoma.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation.PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report.Trial Watch: Radioimmunotherapy for oncological indications.Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.Radiation effects on antitumor immune responses: current perspectives and challenges.CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.Radiation therapy and immunotherapy: what is the optimal timing or sequencing?Optimizing Radiotherapy with Immunotherapeutic Approaches.Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review.Mechanisms and Therapy for Cancer Metastasis to the Brain.Immune checkpoint inhibitors and radiotherapy-concept and review of current literature.Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition Immune checkpoint inhibitors in melanoma

P2860

Q26830509-E64F3FDB-0660-42BD-86F4-87988583C7C1 Q26996518-D34774E4-4926-4158-B97C-E11B73A03FEE Q27005913-16DE372E-13F2-443A-8B3B-FD2B142BC736 Q28081732-5359578A-78E4-43EA-A4CD-E0DDFF6D537F Q33930593-EB861229-90AD-4B45-9F1C-2029A05A038C Q34667662-0DA1875E-A046-4176-8935-73BD2A5DEE08 Q34936394-4C8D5996-F07B-4E82-8752-42AF6EB2F800 Q36046884-E25B1A03-9366-44F3-B9BB-394A4730C9F7 Q36340598-711D46B7-7480-401D-8EF4-BB01ACD6A381 Q36985068-8F22AB03-B887-44CC-95C2-3E98AEC1B452 Q37131014-EBC45097-63F4-4780-96FD-9F7010C3F4A1 Q37551762-F3C2100E-419D-47DB-9430-76A956010FA5 Q37589407-5CC8F66C-CDDB-4E21-B3A0-1BD8136916AA Q37705929-7C4C2ECB-D185-4E35-8BF6-8E363BDF0B42 Q38184650-9A377EF4-08E0-413D-88D1-59B4C2D69C33 Q38391533-210E4F96-1A43-4F84-8F6D-520AF7E80BAE Q38614781-AB78DFCF-0E59-41EE-B747-BF8A946242C9 Q38670716-9E31FDAF-0A15-4478-BC90-38F7BC037819 Q38721253-635B84AB-77F3-41B9-B9DB-26A160F1A1B6 Q38749802-20EB0775-E6B9-4DEE-9ED9-69BB6C51AA24 Q38799946-A1BF5EDA-4069-4EE4-8D9D-CC4F6699AC8A Q38855025-AAA7E529-DF78-4A74-BE2E-B923A30EAE68 Q38964357-8DBA0E97-444C-41A5-9C63-1B94E2E65978 Q39078341-E95F6A44-CC0A-45DB-8DF6-41F76B910F28 Q39099114-E9ACDB58-B75D-4C7A-B56D-3A5B5B92E697 Q39146986-5CD09A73-ABD4-44FE-8338-832A38A36D0F Q43104064-59BC1CAB-729A-4AED-816C-0ABAFC008342 Q47178368-1B1A054B-56DA-477B-835C-96817D3FD27E Q47584286-027ECC9C-004E-4A37-B96C-43DC86A65C11 Q47703452-EA6A3DDC-328B-4533-9AFC-F1DD3B3BE683 Q47862082-BE46A340-ACD2-4BEB-A7DB-D3F7D79F8E58 Q50109474-01EA8852-3811-4DF8-BC4F-EEE7F5FF2055 Q52888621-9C2E6F55-4A93-40F6-95C6-9CED60F501F0 Q54933769-B3B5D140-CC9F-404C-AFBA-8427B962E463 Q54950354-34447792-9253-44DC-9025-8ADA8244E9FD Q55024216-0C2D5525-B27B-49C4-9374-2197E15F4342 Q56892343-6B17B3A8-F155-49E5-869D-5D65EBC4C144 Q56895914-FFE3F60C-76BA-45D3-924E-19A3EDB8A0E6

P2860

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

http://www.wikidata.org/entity/Q36380424

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

@ast

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

@en

type

label

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

@ast

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

@en

prefLabel

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

@ast

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

@en

P1433

Q36380424-6F37CEFE-1641-41BE-8253-D15270954902

P1476

Q36380424-77948076-A834-4760-9362-65DC0E341E72

P2093

Q36380424-1726B362-FA75-46ED-8707-FBBAD6B6E24A

Q36380424-2A813234-2229-486C-8C8B-710F55C86C97

Q36380424-30BB3FE6-2CCA-4D0B-A866-D2EE681E4530

Q36380424-5F846D14-F93D-4623-BE97-7AA83FE8326E

Q36380424-742DD9F4-1A0B-41F6-9FB2-B2CC167989B5

Q36380424-7448D556-BFBB-4F2D-8B5E-CA4B5DD65B74

Q36380424-7C7CBC71-8A06-4C80-8DB0-542121ADDA93

Q36380424-C58140E8-9564-4FBE-A704-025A1E59F514

P2860

Q36380424-06977E4F-E6A2-4E24-87F4-6EA5EAC11BC8

Q36380424-08FE019D-D8FB-4DAC-9746-7638749DBA84

Q36380424-20956031-A8D7-431D-9527-C914942611B0

Q36380424-34DFB054-051A-49DD-A035-00B24090CF53

Q36380424-3A32B29E-DC2F-47F1-A0FB-0EED107F1E7C

Q36380424-3D2C8E51-0FC0-44B2-BB74-9DC96A7503F8

Q36380424-4277C573-299C-4588-9F6A-87AC779351B8

Q36380424-4AE5FAB5-1440-46E6-A178-5B4751C52F95

Q36380424-51F714DC-47AD-457B-A0AB-35EFE668B920

Q36380424-54E68B39-F5DF-4A08-959A-52A00F2C4170

P304

Q36380424-F65BA837-813C-4487-9B92-3E95C03B3034

P31

Q36380424-123C0D36-2AEE-4305-9E19-54CC8B7B422F

P356

Q36380424-5D7DEDFC-957A-4F2D-8AC3-1264D4EEE4D7

P433

Q36380424-D267E6F8-0C93-4ACD-B2EC-4C1271FA376B

P478

Q36380424-5A7D1BD7-F7CD-4D7C-96C6-B64F475FB751

P577

Q36380424-AF2EC4DB-27A9-45B2-B572-44CC802C9D23

P698

Q36380424-0EB5674A-A496-433F-964B-5597C4BECE79

P921

Q36380424-1865E514-8109-44FC-83A8-88063C2E6AC1

Q36380424-635C4B8B-FE9E-47A3-B388-D3401BF11DAE

P932

Q36380424-3A05AED4-1DF8-40DB-B9D9-C3D21C4B0131

P356

2326-6066.CIR-13-0082

P1433

Cancer immunology research

P1476

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

@en

P2093

Christopher A Barker

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Kathryn Beal

http://www.w3.org/2001/XMLSchema#string

Michael A Postow

http://www.w3.org/2001/XMLSchema#string

Nancy Y Lee

http://www.w3.org/2001/XMLSchema#string

Preeti K Parhar

http://www.w3.org/2001/XMLSchema#string

Shaheer A Khan

http://www.w3.org/2001/XMLSchema#string

Yoshiya Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Immunologic correlates of the abscopal effect in a patient with melanoma

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

The abscopal effect associated with a systemic anti-melanoma immune response.

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.

P304

92-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-13-0082

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24777500

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

4682550

http://www.w3.org/2001/XMLSchema#string